Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,628 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT06362148 | Circulating Tumor DNA in Peripheral T-cell Lymphomas(CIRCULATE) | active not recruiting | — | 50 | University of AarhusOTHER | 1 |
| May 1, 2026 |
| clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT03206671 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents(B-NHL 2013) | active not recruiting | Phase 3 | 650 | University Hospital MuensterOTHER | 8 | Apr 30, 2026 | clinicaltrials |
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)(CLL17) | active not recruiting | Phase 3 | 897 | German CLL Study GroupOTHER | 13 | Apr 30, 2026 | clinicaltrials |
| NCT07558057 | Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study(COGNITOX) | not yet recruiting | — | 225 | Aarhus University HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04084249 | ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial | active not recruiting | N/A | 359 | Claus Lindbjerg AndersenOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05428358 | Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery(MAGIPAC) | recruiting | N/A | 200 | University of AarhusOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06040632 | IMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer | active not recruiting | — | 67 | University of AarhusOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06495554 | Danish Vulva Cancer Recurrence Study(DaVulvaRec) | recruiting | N/A | 1,295 | University of AarhusOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07443618 | Measuring Fluid Buildup in Cancer Patients | recruiting | — | 46 | Jens Rikardt AndersenOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT06246227 | ctDNA for Early Detection of Recurrence in Melanoma | active not recruiting | — | 467 | Herlev and Gentofte HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03593018 | Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | completed | Phase 3 | 86 | The Lymphoma Academic Research OrganisationOTHER | 5 | Apr 23, 2026 | clinicaltrials |
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib(SAVANNAH) | active not recruiting | Phase 2 | 367 | AstraZenecaINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT05461313 | Fully Constrained Acetabular Liner vs. Dual Mobility Hip Joint in the Surgical Treatment of Metastatic Bone Disease of the Hip | active not recruiting | N/A | 146 | Rigshospitalet, DenmarkOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548268 | Transoral and Cervical Ultrasound of Patients With Suspected Oropharyngeal Cancer | recruiting | N/A | 180 | Tobias TodsenOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05975073 | A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | completed | Phase 1 / Phase 2 | 53 | AmgenINDUSTRY | 7 | Apr 22, 2026 | clinicaltrials |
| NCT07543601 | Enhanced COPD Management in Suspected Lung Cancer Patients(ECHELON) | recruiting | N/A | 280 | Ditte Krag-HansenOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT03578367 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. | completed | Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 21, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT07531121 | ctDNA for Risk Stratification in Melanoma | active not recruiting | — | 296 | Herlev and Gentofte HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01244789 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | active not recruiting | Phase 2 | 244 | Danish Gynecological Cancer GroupNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT03540420 | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer(ACHILES) | active not recruiting | Phase 2 | 212 | Norwegian University of Science and TechnologyOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT04557150 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | completed | Phase 1 | 225 | Hoffmann-La RocheINDUSTRY | 9 | Apr 13, 2026 | clinicaltrials |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-9) | active not recruiting | Phase 3 | 614 | Janssen Research & Development, LLCINDUSTRY | 24 | Apr 13, 2026 | clinicaltrials |
| NCT06419946 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | recruiting | Phase 3 | 200 | Vastra Gotaland RegionOTHER_GOV | 4 | Apr 13, 2026 | clinicaltrials |
| NCT07263490 | PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)(PRIOR) | recruiting | — | 462 | Copenhagen University Hospital, HvidovreOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis(SENTRY) | active not recruiting | Phase 3 | 353 | Karyopharm Therapeutics IncINDUSTRY | 20 | Apr 9, 2026 | clinicaltrials |
| NCT03772028 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(OVHIPEC-2) | active not recruiting | Phase 3 | 538 | The Netherlands Cancer InstituteOTHER | 7 | Apr 8, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT07518446 | Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)(SomaScreen) | recruiting | N/A | 2,800 | Amager HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04138628 | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy(TOMBOLA) | active not recruiting | Phase 2 | 154 | Jørgen Bjerggaard JensenOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | completed | Phase 1 / Phase 2 | 1,482 | Bristol-Myers SquibbINDUSTRY | 15 | Apr 6, 2026 | clinicaltrials |
| NCT04150120 | eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness(eChildHealth) | completed | N/A | 720 | Lund UniversityOTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT06522737 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype(TERZO) | recruiting | Phase 3 | 124 | SecuraBioINDUSTRY | 10 | Apr 6, 2026 | clinicaltrials |
| NCT04245865 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer(Toco-CoR) | active not recruiting | Phase 2 | 83 | Vejle HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(EXCALIBER-RRMM) | active not recruiting | Phase 3 | 939 | CelgeneINDUSTRY | 31 | Apr 3, 2026 | clinicaltrials |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | active not recruiting | Phase 1 / Phase 2 | 48 | Servier Bio-Innovation LLCINDUSTRY | 15 | Apr 3, 2026 | clinicaltrials |
| NCT06408441 | The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)(EHE) | recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 10 | Apr 3, 2026 | clinicaltrials |
| NCT07510061 | Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals(ICARUS) | recruiting | N/A | 80 | University of ThessalyOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03703050 | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)(NIVO-ALCL) | active not recruiting | Phase 2 | 45 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Apr 2, 2026 | clinicaltrials |
| NCT07460999 | Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)(Sing-a-Lung 2) | recruiting | N/A | 100 | Zealand University HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials